About Prelude Therapeutics Incorporated
https://www.preludetx.comPrelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme.
CEO
Krishna Vaddi
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 1 of 11
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
ORBIMED ADVISORS LLC
Shares:10.91M
Value:$24.65M
BAKER BROS. ADVISORS LP
Shares:10.12M
Value:$22.88M
BOXER CAPITAL, LLC
Shares:1.71M
Value:$3.86M
Summary
Showing Top 3 of 53
About Prelude Therapeutics Incorporated
https://www.preludetx.comPrelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $6.5M ▲ | $26.49M ▼ | $-19.73M ▲ | -303.46% ▼ | $-0.26 ▲ | $-19.3M ▲ |
| Q2-2025 | $0 | $32.19M ▼ | $-31.23M ▲ | 0% | $-0.41 ▲ | $-31.76M ▲ |
| Q1-2025 | $0 ▼ | $34.61M ▼ | $-32.09M ▼ | 0% ▲ | $-0.42 ▼ | $-34.17M ▼ |
| Q4-2024 | $4M ▲ | $37.83M ▲ | $-28.73M ▲ | -718.28% ▲ | $-0.38 ▲ | $-33.34M ▲ |
| Q3-2024 | $3M | $37.38M | $-32.27M | -1.08K% | $-0.43 | $-33.97M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $54.96M ▼ | $94.75M ▼ | $36.22M ▼ | $58.53M ▼ |
| Q2-2025 | $73.22M ▼ | $114.92M ▼ | $39.08M ▲ | $75.84M ▼ |
| Q1-2025 | $99.07M ▼ | $141.26M ▼ | $38.08M ▼ | $103.18M ▼ |
| Q4-2024 | $133.61M ▼ | $175.51M ▼ | $44.06M ▲ | $131.46M ▼ |
| Q3-2024 | $153.63M | $197.22M | $40.79M | $156.43M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-19.73M ▲ | $-19.11M ▲ | $40.09M ▲ | $-5K ▼ | $21.78M ▲ | $-19.11M ▲ |
| Q2-2025 | $-31.23M ▲ | $-26.07M ▲ | $11.52M ▼ | $37K ▲ | $-14.52M ▼ | $-26.09M ▲ |
| Q1-2025 | $-32.09M ▼ | $-34.23M ▼ | $62.19M ▲ | $-160K ▼ | $27.8M ▲ | $-34.28M ▼ |
| Q4-2024 | $-28.73M ▲ | $-20.74M ▲ | $22.12M ▲ | $-34K ▲ | $1.34M ▲ | $-20.8M ▲ |
| Q3-2024 | $-32.27M | $-27.3M | $10.73M | $-131K | $-16.69M | $-27.36M |
CEO
Krishna Vaddi
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 1 of 11
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
ORBIMED ADVISORS LLC
Shares:10.91M
Value:$24.65M
BAKER BROS. ADVISORS LP
Shares:10.12M
Value:$22.88M
BOXER CAPITAL, LLC
Shares:1.71M
Value:$3.86M
Summary
Showing Top 3 of 53